Search clinical trials for: Miransertib (ARQ092)
Total 11 results
-
National Human Genome Research Institute (NHGRI)CompletedProteus SyndromeUnited States
-
National Human Genome Research Institute (NHGRI)Recruiting
-
Merck Sharp & Dohme LLCActive, not recruitingPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)United States, Australia, Brazil, Italy, United Kingdom
-
ArQule, Inc. (a wholly owned subsidiary of Merck...Worldwide Clinical TrialsTerminatedPIK3CA-Related Overgrowth Spectrum (PROS)/Proteus SyndromeUnited States, Australia, Italy, Spain
-
Istituto Oncologico Veneto IRCCSTerminatedCarcinoma, Small CellItaly
-
Daiichi Sankyo, Inc.ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...CompletedHepatocellular CarcinomaUnited States, France, Italy, Germany, Spain, Switzerland, Belgium, Portugal, Netherlands, Australia, Brazil, Canada, Austria, New Zealand, Sweden, Argentina
-
Kyowa Kirin Co., Ltd.Completed
-
Armando Santoro, MDCompletedColorectal Cancer Metastatic | C-met OverexpressionItaly
-
Daiichi Sankyo, Inc.ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...TerminatedNon Squamous, Non-small-cell Lung CancerPoland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
-
Arbor Pharmaceuticals, Inc.TerminatedPhase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09AnesthesiaUnited States